CY1122214T1 - Αντισωματα ειδικα για ton fcrn - Google Patents
Αντισωματα ειδικα για ton fcrnInfo
- Publication number
- CY1122214T1 CY1122214T1 CY20191101125T CY191101125T CY1122214T1 CY 1122214 T1 CY1122214 T1 CY 1122214T1 CY 20191101125 T CY20191101125 T CY 20191101125T CY 191101125 T CY191101125 T CY 191101125T CY 1122214 T1 CY1122214 T1 CY 1122214T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fcrn
- ton
- antibodies specific
- antibodies
- dna
- Prior art date
Links
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 title abstract 2
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Η αποκάλυψη αφορά αντισώματα ειδικά για τον FcRn, σκευάσματα που τα περιέχουν, τη χρήση του καθενός σε θεραπεία, διαδικασίες για την έκφραση και προαιρετικά τη μορφοποίηση του εν λόγω αντισώματος, DNA κωδικοποίησης των αντισωμάτων και ξενιστές που περιλαμβάνουν το εν λόγω DNA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1320066.2A GB201320066D0 (en) | 2013-11-13 | 2013-11-13 | Biological products |
PCT/EP2014/074409 WO2015071330A1 (en) | 2013-11-13 | 2014-11-12 | Antibodies specific to fcrn |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122214T1 true CY1122214T1 (el) | 2020-11-25 |
Family
ID=49818582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191101125T CY1122214T1 (el) | 2013-11-13 | 2019-10-30 | Αντισωματα ειδικα για ton fcrn |
Country Status (31)
Country | Link |
---|---|
US (3) | US10273302B2 (el) |
EP (2) | EP3068800B1 (el) |
JP (2) | JP6584398B2 (el) |
KR (1) | KR102366114B1 (el) |
CN (1) | CN105814080B (el) |
AR (1) | AR098408A1 (el) |
AU (1) | AU2014350257B2 (el) |
BR (1) | BR112016010822A2 (el) |
CA (1) | CA2928341A1 (el) |
CL (2) | CL2016001147A1 (el) |
CY (1) | CY1122214T1 (el) |
DK (1) | DK3068800T3 (el) |
EA (1) | EA035142B1 (el) |
ES (1) | ES2748570T3 (el) |
GB (1) | GB201320066D0 (el) |
HR (1) | HRP20192006T1 (el) |
HU (1) | HUE046511T2 (el) |
IL (1) | IL245265B (el) |
LT (1) | LT3068800T (el) |
MA (1) | MA39096B1 (el) |
MX (1) | MX2016005956A (el) |
PE (1) | PE20160662A1 (el) |
PH (1) | PH12016500753A1 (el) |
PL (1) | PL3068800T3 (el) |
PT (1) | PT3068800T (el) |
SG (1) | SG11201603307XA (el) |
SI (1) | SI3068800T1 (el) |
TN (1) | TN2016000173A1 (el) |
TW (1) | TWI651330B (el) |
UY (1) | UY35835A (el) |
WO (1) | WO2015071330A1 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
EP2992012B1 (en) | 2013-04-29 | 2019-07-17 | F.Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
GB201320066D0 (en) * | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
EP3842455A1 (en) | 2014-01-15 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with improved protein a-binding |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
US10822417B2 (en) * | 2016-04-25 | 2020-11-03 | Syntimmune, Inc. | Humanized affinity matured anti-FcRn antibodies |
CA3116091A1 (en) | 2018-10-16 | 2020-04-23 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
US11926669B2 (en) | 2022-05-30 | 2024-03-12 | Hanall Biopharma Co., Ltd. | Anti-FcRn antibody or antigen binding fragment thereof with improved stability |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1638A (en) | 1872-08-31 | J.M. Taylor | Improvement on railway snow-plows | |
DE2063975C3 (de) | 1970-12-28 | 1973-09-27 | Deutsche Vergaser Gmbh & Co Kg, 4040 Neuss | Brennstoffzumeßduse mit temperatur abhangig veränderbarem Austrittsquer schnitt fur Vergaser insbesondere Gleich druckvergaser, fur Brennkraftmaschinen |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
WO2002043658A2 (en) | 2000-11-06 | 2002-06-06 | The Jackson Laboratory | Fcrn-based therapeutics for the treatment of auto-immune disorders |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
US7889182B2 (en) * | 2002-10-04 | 2011-02-15 | Lancer Partnership, Ltd. | Multiple brand ice beverage dispenser |
JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
WO2005003169A2 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
US20050079169A1 (en) * | 2003-08-08 | 2005-04-14 | Balthasar Joseph P. | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
GB0506912D0 (en) * | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
WO2006118772A2 (en) | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
AU2008284047A1 (en) | 2007-08-09 | 2009-02-12 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
WO2009080764A2 (en) | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
CA2722082C (en) * | 2008-04-25 | 2021-11-09 | Christopher Tenhoor | Fc receptor binding proteins |
US20100048488A1 (en) | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
HUE033438T2 (en) | 2008-09-26 | 2017-11-28 | Ucb Biopharma Sprl | Biological products |
EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
EP2714084B1 (en) * | 2011-06-02 | 2019-05-22 | Dyax Corp. | Fc RECEPTOR BINDING PROTEINS |
PT2776466T (pt) | 2011-11-11 | 2017-11-30 | Ucb Biopharma Sprl | Anticorpos de ligação a albumina e seus fragmentos de ligação |
KR20130071961A (ko) * | 2011-12-21 | 2013-07-01 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
GB201320066D0 (en) * | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
-
2013
- 2013-11-13 GB GBGB1320066.2A patent/GB201320066D0/en not_active Ceased
-
2014
- 2014-11-12 PL PL14800000T patent/PL3068800T3/pl unknown
- 2014-11-12 EP EP14800000.3A patent/EP3068800B1/en active Active
- 2014-11-12 EP EP19182386.3A patent/EP3572433A1/en not_active Withdrawn
- 2014-11-12 CA CA2928341A patent/CA2928341A1/en not_active Abandoned
- 2014-11-12 DK DK14800000.3T patent/DK3068800T3/da active
- 2014-11-12 SG SG11201603307XA patent/SG11201603307XA/en unknown
- 2014-11-12 TN TN2016000173A patent/TN2016000173A1/en unknown
- 2014-11-12 SI SI201431341T patent/SI3068800T1/sl unknown
- 2014-11-12 BR BR112016010822A patent/BR112016010822A2/pt not_active IP Right Cessation
- 2014-11-12 ES ES14800000T patent/ES2748570T3/es active Active
- 2014-11-12 KR KR1020167015565A patent/KR102366114B1/ko active IP Right Grant
- 2014-11-12 PT PT148000003T patent/PT3068800T/pt unknown
- 2014-11-12 JP JP2016530139A patent/JP6584398B2/ja not_active Expired - Fee Related
- 2014-11-12 US US15/036,209 patent/US10273302B2/en not_active Expired - Fee Related
- 2014-11-12 WO PCT/EP2014/074409 patent/WO2015071330A1/en active Application Filing
- 2014-11-12 PE PE2016000616A patent/PE20160662A1/es unknown
- 2014-11-12 LT LT14800000T patent/LT3068800T/lt unknown
- 2014-11-12 MA MA39096A patent/MA39096B1/fr unknown
- 2014-11-12 MX MX2016005956A patent/MX2016005956A/es unknown
- 2014-11-12 CN CN201480062110.9A patent/CN105814080B/zh not_active Expired - Fee Related
- 2014-11-12 AU AU2014350257A patent/AU2014350257B2/en not_active Ceased
- 2014-11-12 EA EA201690992A patent/EA035142B1/ru not_active IP Right Cessation
- 2014-11-12 HU HUE14800000A patent/HUE046511T2/hu unknown
- 2014-11-13 AR ARP140104270A patent/AR098408A1/es unknown
- 2014-11-13 UY UY0001035835A patent/UY35835A/es not_active Application Discontinuation
- 2014-11-13 TW TW103139360A patent/TWI651330B/zh not_active IP Right Cessation
-
2016
- 2016-04-21 IL IL245265A patent/IL245265B/en active IP Right Grant
- 2016-04-22 PH PH12016500753A patent/PH12016500753A1/en unknown
- 2016-05-12 CL CL2016001147A patent/CL2016001147A1/es unknown
-
2019
- 2019-03-12 US US16/299,407 patent/US11220547B2/en active Active
- 2019-06-17 CL CL2019001671A patent/CL2019001671A1/es unknown
- 2019-09-03 JP JP2019160103A patent/JP2020018301A/ja active Pending
- 2019-10-30 CY CY20191101125T patent/CY1122214T1/el unknown
- 2019-11-06 HR HRP20192006TT patent/HRP20192006T1/hr unknown
-
2021
- 2021-12-09 US US17/643,506 patent/US20220162311A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
CY1124096T1 (el) | Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης | |
CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
CY1124445T1 (el) | Αντισωματα αντι-ccl17 | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. |